COVID-19 vaccine effectiveness
(Randomized evidence)
If you want to see all comparisons, please click here
University of Oxford/AstraZeneca - ChAdOx1 nCoV-19 vs Placebo
You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.
Forest plots
(last update: 2021-02-25)
Summary of findings
2021-02-26
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04400838 AstraZeneca + University of Oxford Emary K, Lancet, 2021 Full text Commentary |
Non replicating viral vector |
ChAdOx1 |
MenACWY |
RCTPhase 2-3 | Adults seronegative at baseline enrolled at 19 study sites in UK | N=10673 |
Some concerns Details |
|
|
NCT04324606; ISRCTN1 University of Oxford/AstraZeneca Folegatti PM, Lancet, 2020 COV001 Full text Commentary ; Commentary (20)31611-1/fulltext |
Non replicating viral vector |
ChAdOx1 SD |
MenACWY |
RCTPhase 1 - 2 | Healthy adults with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms in five centres in the UK | N=1067 |
Low Details |
|
|
NCT04444674 University of Oxford/AstraZeneca Madhi S, N Engl J Med, 2021 COV005 Full text Commentary |
Non replicating viral vector |
ChAdOx1 |
Placebo |
RCTPhase 1-2 | Healthy adult volunteers that were HIV-negative and SARS-CoV-2 infection-free in 7 centres in South Africa | N=2026 |
Some concerns Details |
|
|
NCT04444674, PACTR202006922165132 AstraZeneca + University of Oxford Madhi S, Research square , 2021 Full text Commentary |
Non replicating viral vector |
ChAdOx1 nCoV-19 |
Placebo D0/28 |
RCTPhase 1-2 | Adults living with HIV in 7 centers in South Africa | N=104 |
Some concerns Details |
|
|
ISRCTN89951424 University of Oxford/AstraZeneca Voysey M, Lancet, 2020 COV003 Full text Commentary |
Non replicating viral vector |
ChAdOx1 SD/SD |
MenACWY/saline |
RCTPhase 3 | Healthy SARS-CoV-2 serology/DNA negative adults in six centres in Brazil | N=10002 |
Some concerns Details |
|
|
NCT04400838 University of Oxford/AstraZeneca Voysey M, Lancet, 2020 COV002 Full text Commentary |
Non replicating viral vector |
ChAdOx1 LD/SD ChAdOx1 SD/SD |
MenACWY |
RCTPhase 2/3 | Healthy adults in 18 centres in the UK | N=10673 |
Some concerns Details |
|
|
NCT04324606 / EudraC AstraZeneca + University of Oxford Voysey M, Lancet, 2021 COV001/COV002/COV003/COV005 Full text Commentary ; Commentary ; Commentary |
Non replicating viral vector |
ChAdOx1 |
MenACWY/saline |
RCTphase 1/2/3 | Adults seronegative at baseline from four studies in multiple centres in Brazil, South Africa, and the UK | N=24422 |
Some concerns Details |
|